The "Million Dollar Anti Cancer Drug" is New! Legendary Biology's Entry into the Domestic Market and Pricing Attention. Can CAR-T Therapy Break the Four Warring States Talks? This year's H1 global sales exceeded 300 million US dollars, and Legendary Biology's Xidakuolunsai Injection (trade name: Kaweidi) was approved for sale in China on the 27th. In order to enhance the commercial value, domestic CAR-T enterprises, in addition to exploring more indications, will continue to participate in national talks this year and hope to enter medical insurance with multiple CAR-T therapies. Industry experts believe that CAR-T therapy has a wide range of application prospects, and in this year's medical insurance negotiations, the national negotiation team and pharmaceutical companies will tend to be more rational about the value of CAR-T therapy.